Dr. Schmidt on AMAROS Trial Results: Radiotherapy vs Surgery of the Axilla in Breast Cancer

Video

Cancer Network spoke with Hank Schmidt, MD, about the 10-year follow-up results of the EORTC AMAROS trial of radiotherapy vs surgery of the axilla in breast cancer patients with a positive sentinel node.

Cancer Network spoke with Hank Schmidt, MD, about the 10-year follow-up results of the European Organisation for Research and Treatment of Cancer (EORTC) AMAROS trial comparing radiotherapy to surgery of the axilla in breast cancer patients with a positive sentinel node.

Recent Videos
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Related Content
Notably, improvements in both the ESR1 mutated population and the intent-to-treat population, including ESR1 wild type, were announced, and data will be presented at an upcoming scientific meeting.

Awareness Fuels Progress: Upcoming Advances in Breast Cancer Treatment

Neil M. Iyengar, MD
October 24th 2025
Article

Read about recent advancements in breast cancer treatment, including new therapies and survival data, showcased at the upcoming ESMO 2025 Congress.

Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 8th 2025
Podcast

Up-front risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Dato-DXd May Be Next SOC in First-Line TNBC

Dato-DXd May Be Next SOC in First-Line TNBC

Kristi Rosa
October 20th 2025
Article

Datopotamab deruxtecan significantly enhanced survival rates in first-line treatment for metastatic triple-negative breast cancer.

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Trastuzumab rezetecan may represent a promising practice-changing therapeutic in this breast cancer population based on data from HORIZON-Breast01.

PFS Benefit Occurs With Trastuzumab Rezetecan in HER2+ Breast Cancer

Jason M. Broderick
October 19th 2025
Article

Trastuzumab rezetecan may represent a promising practice-changing therapeutic in this breast cancer population based on data from HORIZON-Breast01.

T-DXd showed a consistent duration of response advantage vs THP regardless of prior treatment and mutational status among HER2+ breast cancer subgroups.

Subgroup Analysis Yields Clinically Meaningful Responses With T-DXd in HER2+ Breast Cancer

Ariana Pelosci
October 19th 2025
Article

T-DXd showed a consistent duration of response advantage vs THP regardless of prior treatment and mutational status among HER2+ breast cancer subgroups.